The percentage of male diabetics, age 50 years or older, or female diabetics, aged 60 years or older, with a Framingham risk score > 10 who are taking aspirin or an antiplatelet agent.
-
-
1.5 Measure Type1.7 Electronic Clinical Quality Measure (eCQM)1.8 Level Of Analysis1.9 Care Setting
-
1.14 Numerator
Patients with a refill for aspirin or antiplatelet therapy in the past 6 months
-
1.15 Denominator
Male diabetics, age 50 years or older, or female diabetics, aged 60 years or older, with a Framingham risk score > 10.
-
Exclusions
Specific Exclusions:
1. Contraindications to aspirin therapy, including:
- Hemorrhage contraindications and procedures
- Neutropenia
- Thrombocytopenia
- Hematocrit lab value </= 25
- INR lab value > 1.6
- Platelet lab value </= 50
- WBC lab value < 2.0
- Chronic liver disease
- Aspirin intolerance
- Aspirin-induced asthma
- Intracerebral hemorrhage
- Coagulopathies (bleeding disorders)
2. Other denominator exclusions include:
- Warfarin use
- Long term anticoagulation therapy
General exclusions:
1. Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months;
2. Patients who have been in a skilled nursing facility in the last 3 months
3. Patients who are terminally ill or in Hospice
4. Patient or provider feedback indicating allergy, intolerance or other contraindication to Aspirin or Antiplatelet therapy anytime in the past
See attachment for code sets
-
Most Recent Endorsement ActivityMeasure Retired and Endorsement Removed National Voluntary Consensus Standards For Clinically Enriched Administrative DataInitial EndorsementLast UpdatedRemoval Date
-
StewardSteward Organization Email
-
-
-
Risk Adjustment
-
-
-
6.1.2 Current or Planned Use(s)6.1.3 Current Use(s)
-